Why Is AI-Based Heart Disease Focused Cardio Diagnostics Stock Trading Higher Today?

Cardio Diagnostics Holdings Inc CDIO announced the publication of its study in the Journal of the American Heart Association (JAHA), an official journal of the American Heart Association. 

Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. 

This study, conducted in collaboration with Intermountain Healthcare and University of Iowa Hospitals and Clinics, describes the development and validation of PrecisionCHD, an artificial intelligence-guided integrated genetic-epigenetic test for detecting coronary heart disease (CHD).

The study detailed in JAHA was conducted in three independent cohorts totaling 2,516 individuals. 

PrecisionCHD is the first integrated genetic-epigenetic test for the detection of CHD that uses the input from six methylation-sensitive digital PCR (MSdPCR) assessments to determine the presence or absence of CHD.

The article details the mapping of these MSdPCR assays to distinct modifiable drivers of CHD through which clinicians can gain personalized insights into each patient's CHD presentation. 

PrecisionCHD's ability to be administered in primary care or telemedicine settings significantly reduces the need for patients from rural communities to travel to distant specialized clinics. 

Price Action: CDIO shares are up 76.76% at $1.75 on the last check Monday.